Recital 1, Directive (EU) 2025/2062

In forcesince 14 Oct 2025

Risk assessment reports on the new psychoactive substances 2-methylmethcathinone (2-MMC), N-ethylnorpentedrone (NEP) and 4-bromomethcathinone (4-BMC) were drawn up in compliance with Article 10 of Regulation (EU) 2023/1322 of the European Parliament and of the Council [Regulation (EU) 2023/1322 of the European Parliament and of the Council of 27 June 2023 on the European Union Drugs Agency (EUDA) and repealing Regulation (EC) No 1920/2006 (OJ L 166, 30.6.2023, p. 6, ELI: http://data.europa.eu/eli/reg/2023/1322/oj).] by the Scientific Committee of the European Union Drugs Agency (the Agency), extended following the procedure laid down in Article 10(4) of that Regulation, on 20 and 21 May 2025. The Agency submitted the risk assessment reports to the Commission and to the Member States on 27 May 2025.